Education
About Us
Working with TipRanks
Follow Us
GeneTether Therapeutics, Inc. (TSE:RIZE)
:RIZE
RESEARCH TOOLSreports
Total Valuation
GeneTether Therapeutics, Inc. has a market cap or net worth of C$2.27M. The enterprise value is ―.
Market CapC$2.27M
Enterprise Value―
Share Statistics
GeneTether Therapeutics, Inc. has 75,744,675 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding75,744,675
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
GeneTether Therapeutics, Inc.’s return on equity (ROE) is ― and return on invested capital (ROIC) is ―.
Return on Equity (ROE)―
Return on Assets (ROA)―
Return on Invested Capital (ROIC)―
Return on Capital Employed (ROCE)―
Revenue Per Employee―
Profits Per Employee-10.00T>
Employee Count―
Asset Turnover―
Inventory Turnover―
Valuation Ratios
The current PE Ratio of GeneTether Therapeutics, Inc. is ―. GeneTether Therapeutics, Inc.’s PEG ratio is ―.
PE Ratio―
PS Ratio0.00
PB Ratio―
Price to Fair Value―
Price to FCF―
Price to Operating Cash Flow―
PEG Ratio―
Income Statement
In the last 12 months, GeneTether Therapeutics, Inc. had revenue of 0.00 and earned -688.36K in profits. Earnings per share was -0.01.
Revenue0.00
Gross Profit0.00
Operating Income-747.28K
Pretax Income-688.36K
Net Income-688.36K
EBITDA0.00
Earnings Per Share (EPS)-0.01
Cash Flow
In the last 12 months, operating cash flow was -393.18K and capital expenditures 0.00, giving a free cash flow of -393.18K billion.
Operating Cash Flow-393.18K
Free Cash Flow-393.18K
Free Cash Flow per Share>-0.01
Dividends & Yields
GeneTether Therapeutics, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.38
52-Week Price Change50.00%
50-Day Moving Average0.06
200-Day Moving Average0.07
Relative Strength Index (RSI)45.52
Average Volume (3m)5.89K
Important Dates
GeneTether Therapeutics, Inc. upcoming earnings date is May 22, 2025, TBA Not Confirmed.
Last Earnings DateApr 24, 2025
Next Earnings DateMay 22, 2025
Ex-Dividend Date―
Financial Position
GeneTether Therapeutics, Inc. as a current ratio of ―, with Debt / Equity ratio of ―
Current Ratio―
Quick Ratio―
Debt to Market Cap―
Net Debt to EBITDA―
Interest Coverage Ratio―
Taxes
In the past 12 months, GeneTether Therapeutics, Inc. has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate―
Enterprise Valuation
GeneTether Therapeutics, Inc. EV to EBITDA ratio is ―, with an EV/FCF ratio of ―.
EV to Sales―
EV to EBITDA―
EV to Free Cash Flow―
EV to Operating Cash Flow―
Balance Sheet
GeneTether Therapeutics, Inc. has C$966.11K in cash and marketable securities with $0.00 in debt, giving a net cash position of -C$966.11K billion.
Cash & Marketable SecuritiesC$966.11K
Total Debt$0.00
Net Cash-C$966.11K
Net Cash Per Share-C$0.01
Tangible Book Value Per Share―
Margins
Gross margin is ―, with operating margin of ―, and net profit margin of ―.
Gross Margin―
Operating Margin―
Pretax Margin―
Net Profit Margin―
EBITDA Margin―
EBIT Margin―
Analyst Forecast
The average price target for GeneTether Therapeutics, Inc. is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast-20.10%